Veracyte Unveils AUA 2026 Data Showing Decipher Tests' Role in Urologic Cancer Personalization
Event summary
- Veracyte to present 15+ studies on Decipher portfolio at AUA 2026 (May 15-18)
- New data highlights molecular subtyping in bladder cancer using Decipher Bladder test
- Real-world evidence from Decipher Prostate shows impact on treatment decisions
- Decipher GRID database fuels ongoing research with 200,000+ whole-transcriptome profiles
The big picture
Veracyte's AUA 2026 data presentations underscore the growing role of genomic classifiers in precision oncology, particularly as payers and clinicians demand evidence linking molecular insights to tangible treatment outcomes. The company's ability to leverage its Decipher GRID database positions it uniquely in the urologic cancer diagnostics space, where real-world data is becoming increasingly critical for validating diagnostic tools.
What we're watching
- Clinical Adoption
- How quickly urologists integrate molecular subtyping into standard bladder cancer treatment protocols following these data presentations.
- Regulatory Pathways
- Whether the real-world evidence from Decipher Prostate accelerates expanded guideline inclusion or reimbursement coverage.
- Competitive Positioning
- The pace at which Veracyte can differentiate its diagnostics platform against emerging genomic testing alternatives in urologic oncology.
Related topics